Mirum Pharmaceuticals (MIRM) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MIRM Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Mirum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$103.10 |
| 52 Week High | US$105.74 |
| 52 Week Low | US$36.88 |
| Beta | 0.50 |
| 1 Month Change | 13.23% |
| 3 Month Change | 42.82% |
| 1 Year Change | 106.04% |
| 3 Year Change | 332.65% |
| 5 Year Change | 430.35% |
| Change since IPO | 680.47% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25%
Jan 28
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026
Dec 22Mirum Pharmaceuticals (NASDAQ:MIRM) Is Carrying A Fair Bit Of Debt
Oct 16Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Aug 11
FDA And Japanese Approvals Will Open New Markets
Strong revenue growth and recent regulatory approvals are set to expand market reach and positively impact future revenues.Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like
Mar 24Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 21Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Jan 08Mirum Pharma: Buy At Dips For Volixibat Potential
Dec 25Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05Shareholder Returns
| MIRM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.5% | -1.1% | -1.3% |
| 1Y | 106.0% | 27.6% | 10.9% |
Return vs Industry: MIRM exceeded the US Biotechs industry which returned 27.6% over the past year.
Return vs Market: MIRM exceeded the US Market which returned 10.9% over the past year.
Price Volatility
| MIRM volatility | |
|---|---|
| MIRM Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MIRM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MIRM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 355 | Chris Peetz | www.mirumpharma.com |
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis.
Mirum Pharmaceuticals, Inc. Fundamentals Summary
| MIRM fundamental statistics | |
|---|---|
| Market cap | US$6.17b |
| Earnings (TTM) | -US$41.42m |
| Revenue (TTM) | US$471.79m |
Is MIRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MIRM income statement (TTM) | |
|---|---|
| Revenue | US$471.79m |
| Cost of Revenue | US$94.76m |
| Gross Profit | US$377.04m |
| Other Expenses | US$418.46m |
| Earnings | -US$41.42m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 79.92% |
| Net Profit Margin | -8.78% |
| Debt/Equity Ratio | 105.9% |
How did MIRM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/16 12:17 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mirum Pharmaceuticals, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |